Top photo: © mokee81 | Adobe Stock
Canopy Growth Corp. has entered into a first-of-its-kind partnership with the NHL Alumni Association (NHLAA) and NEEKA Health Canada to explore cannabis-based neurological treatments for athletes.
The partnership will begin with a double-blind clinical trial involving about 100 former hockey stars, and is aimed to reduce reliance on highly-addictive opioids and other pharmaceutical painkillers.
NHLAA executive director Glenn Healy made the announcement in Toronto on Saturday, flanked on stage by former players. He said the hardest part of his job has been receiving calls from players’ families as they cope with the neurological consequences of years on the ice.
